Valentina Mengardo

Valentina Mengardo

Auto-generated profile, based on publicly available information

Valentina Mengardo

University of Verona

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JWJacopo Weindelmayer
Jacopo Weindelmayer
VMValentina Mengardo
Valentina Mengardo
AGAngela Gasparini
Angela Gasparini
MSMichele Sacco
Michele Sacco
LTLorena Torroni
Lorena Torroni
GMGiovanni de Manzoni
Giovanni de Manzoni
Background: Data on ERAS for gastrectomy are scarce, and the majority of the studies come from Eastern countries. Patients in the West are older and suffer from more advanced tumors that impair their clinical condition and often require neoadjuvant treatment. This retrospective study assessed the feasibility and safety of an Enhanced Recovery After Surgery (ERAS) protocol for gastrectomy in a Western center. Methods: We conducted a single-center study of 351 patients operated for gastric cancer: 103, operated from January 2015 to December 2016, followed the standard pathway, while 248, operated from January 2017 to December 2019, followed the ERAS program. The primary outcomes considered were length of hospital stay (LOS) and direct costs. Secondary outcomes were 90-day morbidity and mortality, readmission rate, and compliance with ERAS items. A propensity score (PS) was built on confounding variables. Results: Compliance with ERAS items after the program was ≥ 70%. Univariable analysis evidenced a 2-day median reduction in LOS and a median cost reduction of €826 per patient in the ERAS group. PS-based multivariable analysis confirmed a significant, 2-day decrease in median LOS and a €1097 saving after ERAS introduction. Ninety-day mortality decreased slightly in ERAS group, while complications and readmissions did not change significantly. When complications were included in the multivariable analysis, ERAS retained its significance, although the effects on LOS and cost were blunted to a median reduction of 1 day and €775, respectively. Conclusions: ERAS for gastrectomy improved patients’ recovery and reduced hospital costs without changes in morbidity, mortality, or readmission.

1 August 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JWJacopo Weindelmayer
Jacopo Weindelmayer
VMValentina Mengardo
Valentina Mengardo
Alessandro VeltriAlessandro Veltri
Alessandro Veltri
Lorena TorroniLorena Torroni
Lorena Torroni
EZEnhao Zhao
Enhao Zhao
GMGiovanni de Manzoni
Giovanni de Manzoni

29 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MMManlio Monti
Manlio Monti
PMPaolo Morgagni
Paolo Morgagni
ONOriana Nanni
Oriana Nanni
MFMassimo Framarini
Massimo Framarini
LSLuca Saragoni
Luca Saragoni
GFGiovanni Luca Frassineti
Giovanni Luca Frassineti
Docetaxel associated with oxaliplatin and 5-fluorouracil (FLOT) has been reported as the best perioperative treatment for gastric cancer. However, there is still some debate about the most appropriate number and timing of chemotherapy cycles. In this randomized multicenter phase II study, patients with resectable gastric cancer were staged through laparoscopy and peritoneal lavage cytology, and randomly assigned (1:1) to either four cycles of neoadjuvant chemotherapy (arm A) or two preoperative + two postoperative cycles of docetaxel, oxaliplatin, and capecitabine (DOC) chemotherapy (arm B). The primary endpoint was to assess the percentage of patients receiving all the planned preoperative or perioperative chemotherapeutic cycles. Ninety-one patients were enrolled between September 2010 and August 2016. The treatment was well tolerated in both arms. Thirty-three (71.7%) and 24 (53.3%) patients completed the planned cycles in arms A and B, respectively (p = 0.066), reporting an odds ratio for early interruption of treatment of 0.45 (95% confidence interval (CI): 0.18–1.07). Resection was curative in 39 (88.6%) arm A patients and 35 (83.3%) arm B patients. Five-year progression-free survival (PFS) was 51.2% (95% CI: 34.2–65.8) in arm A and 40.3% (95% CI: 28.9–55.2) in arm B (p = 0.300). Five-year survival was 58.5% (95% CI: 41.3–72.2) and 53.9% (95% CI: 35.5–69.3) (p = 0.883) in arms A and B, respectively. The planned treatment was more frequently completed and was more active, albeit not significantly, in the neoadjuvant arm than in the perioperative group.

9 June 2018 in Updates in Surgery
Verified
Journal Article
Closed access
VMV. Mengardo
V. Mengardo
ETE. Treppiedi
E. Treppiedi
MBM. Bencivenga
M. Bencivenga
MCMariagiulia Dal Cero
Mariagiulia Dal Cero
SGS. Giacopuzzi
S. Giacopuzzi

1 February 2019 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
FCF. Catalano
F. Catalano
VMV. Mengardo
V. Mengardo
ATA. Trecca
A. Trecca
ATA. Tomezzoli
A. Tomezzoli
LRL. Rodella
L. Rodella
GMG. de Manzoni
G. de Manzoni

4 June 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
VMValentina Mengardo
Valentina Mengardo
OCOrla Mc Cormack
Orla Mc Cormack
JWJacopo Weindelmayer
Jacopo Weindelmayer
ACAsif Chaudry
Asif Chaudry
MBMaria Bencivenga
Maria Bencivenga
GMGiovanni de Manzoni
Giovanni de Manzoni